Search company, investor...
Ubiquigent company logo



Unattributed VC | Alive

Total Raised


About Ubiquigent

Ubiquigent develops and provides a range of reagents, kits, assay development, drug lead compound profiling (including DUBprofiler for profiling deubiquitylase enzyme inhibitors) and other services. These products and services support academic and pharmaceutical researchers to understand the role of protein ubiquitylation in regulating many aspects of cellular functions and the development and optimization of drug candidate compounds that target the system addressing a number of critical therapeutic areas.

Headquarters Location

Sir James Black Centre Dow Street

Dundee, Scotland, DD1 5EH,

United Kingdom

+1 617 245 0020

Missing: Ubiquigent's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ubiquigent's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ubiquigent

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ubiquigent is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Ubiquigent News

Ubiquigent and University of Glasgow to collaborate on drug discovery

Jan 24, 2023

Photo/Shutterstock Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative , renal, and cardiovascular diseases. Overseen by structural biology experts Helen Walden, UoG, and Mehmet Gundogdu, principal scientist at Ubiquigent, the project aims to combine biochemistry, in vitro complex protein assembly and protein crystallography to interrogate the mechanism underlying USP30 inhibition by selected proprietary compounds. As well as promoting fundamental research on this strategic enzyme, the project will assist Ubiquigent’s USP30 program. The studentship is fully funded by Ubiquigent. Mitophagy USP30 regulates the clearance of damaged mitochondria in a process called mitophagy. Dysregulation of mitophagy is closely linked to the development of several diseases, with USP30 modulation offering a potential treatment; USP30 inhibition, for example, has been proposed as a therapeutic strategy for Parkinson’s disease (PD). Although numerous USP30-targeting compounds are reported in scientific literature, only one has been approved to enter clinical evaluation so far, and the design and discovery of new compounds is hampered by a lack of a suitable USP30 crystal structure in the public domain. The project aims to overcome this barrier, bringing together the expertise of both groups to deliver a bespoke USP30 structural biology platform to identify novel inhibitors for treatment of a range of diseases including PD. Helen Walden, professor of Structural Biology, Head of School (Molecular Biosciences), University of Glasgow, said: “There is huge potential to exploit USP30 as a therapeutic target across many indications, including cardiovascular, renal, and neurodegenerative diseases. My team has worked extensively on resolving the structures of both DUBs and E3 ligases, and I look forward to combining this experience with Ubiquigent’s drug discovery expertise to support the Master’s student and resolve the crystal structure of USP30 for the design of novel therapeutics.” Mehmet Gundogdu, principal scientist, Ubiquigent, added: “Collaborating with Professor Walden on this project is an exciting opportunity to combine forces in an important therapeutic area. USP30 is a prominent target in the DUB drug discovery space, and this project has great potential to enable the structure-led design and development of novel USP30 modulators.” Content continues below Related Content Sheelagh Frame, chief scientific officer, Ubiquigent, concluded: “We are delighted to support the Master’s student, Niyati Gupta Kheskani, in Professor Walden’s laboratory. By determining the structure of USP30 in complex with proprietary inhibitor compounds, our joint objective is to further enable USP30-focused drug discovery and move one step closer to the clinic. This is a great opportunity to support the development of the next generation of scientists, as well as to strengthen our relationship with Professor Walden and her team.” Explore Related Topics:

Ubiquigent Frequently Asked Questions (FAQ)

  • Where is Ubiquigent's headquarters?

    Ubiquigent's headquarters is located at Sir James Black Centre, Dundee.

  • What is Ubiquigent's latest funding round?

    Ubiquigent's latest funding round is Unattributed VC.

  • How much did Ubiquigent raise?

    Ubiquigent raised a total of $800K.

  • Who are the investors of Ubiquigent?

    Investors of Ubiquigent include IP Group, Innovate UK and Scottish Investment Bank.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.